[Clinical research progress in 2025 for hepatic fibrosis, cirrhosis, and portal hypertension]. [PDF]
Han YF, Xu XY.
europepmc +1 more source
[Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)]. [PDF]
Chinese Society of Hepatology +1 more
europepmc +1 more source
[Research progress on predictive models of portal vein thrombosis in liver cirrhosis]. [PDF]
Wu ZN +5 more
europepmc +1 more source
[Clinical research progress in different stages of recompensated cirrhosis]. [PDF]
Wang YP +6 more
europepmc +1 more source
[Progress in the treatment of sarcopenia in patients with cirrhosis]. [PDF]
Zhang JT +5 more
europepmc +1 more source
[A case of liver cirrhosis combined with reactive perforating collagen disease]. [PDF]
Han XX, Zhang ZJ, Wang QY.
europepmc +1 more source
[Cirrhosis recompensation: clinical complications]. [PDF]
Wang Q, Xie W.
europepmc +1 more source
[A case of cirrhosis combined with myeloproliferative neoplasms]. [PDF]
Li WC, Zhao SX, Liu SH, Han F, Nan YM.
europepmc +1 more source
[Histopathological evaluation of cirrhosis reversal]. [PDF]
Zhang W, Sun YM, Chen SY, You H.
europepmc +1 more source
肝炎后肝硬化患者尿血栓素B2和6-酮-前列腺素F1α与肾功能的关系
用放射免疫法测定了45例肝炎后肝硬化患者尿血栓素B2和6-酮-前列腺素F1α的排泄率。结果,肝硬化患者尿血栓素B2排泄率较正常对照明显升高;肝硬化无并肾衰者尿6-酮-PGF1α较对照组升高;但并有肾衰者尿6-酮-前列腺素F1α排泄率比无并肾衰者则显著降低 ...
doaj

